Spiky metal-organic framework nanosystem for enhanced cuproptosis-mediated cancer immunotherapy
Source abstract
Abstract
Immunotherapy, particularly αPD-1 therapy, has been hailed as a significant breakthrough in cancer treatment. However, the limited response rates and unknown mechanisms hinder the clinical application of αPD-1 blockade boosting with hybrid nanoparticles. Herein, we introduce a strategy to enhance cancer immunotherapy by leveraging cuproptosis, initiated by the spiky copper-based metal-organic framework (S@Cu-MOF) loaded with polyphyllin I (PPI) and synergized with αPD-1 therapy. Interestingly, the unique spiky structure of S@Cu-MOF not only significantly enhances tumor cell uptake but also leads to pronounced DNA damage. The application of S@Cu-MOF/PPI with αPD-1 therapy led to obvious tumor regression and prolonged survival due to cuproptosis, which involved substantial mitochondrial damage. This process amplifies the cGAS/STING immune pathway, enhancing the immune response against cancer. Additionally, this strategy promoted immunogenic cell death (ICD), recruitment of mature dendritic cells (DCs), T cell-mediated immunity, and effective memory CD8+ T cells, resulting in significant abscopal tumor suppression and lung metastasis reduction. Our study highlights the potential of S@Cu-MOF/PPI as a sensitizer for αPD-1 with the mechanism of cuproptosis and the cGAS/STING pathway, offering a promising strategy for the next generation of immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Liu · Signal Transduct. Target Ther. · 2023 · 8 · 10410.1038/s41392-023-01365-z ↗
2. Fusco · JAMA Oncol. · 2021 · 710.1001/jamaoncol.2020.6371 ↗
3. Chu · Mol. Cancer · 2023 · 22 · 1
4. Lu · Innovation · 2020 · 1
5. Gong · J. Immunother. Cancer · 2018 · 6 · 1
6. Tisato · Med. Res. Rev. · 2010 · 30 · 70810.1002/med.20174 ↗
7. Guan · Biomed. Pharmacother. · 2023 · 16310.1016/j.biopha.2023.114791 ↗
8. Ji · Free Radic. Biol. Med. · 2018 · 129 · 21510.1016/j.freeradbiomed.2018.09.017 ↗
9. Chen · Signal Transduct. Target Ther. · 2022 · 7 · 37810.1038/s41392-022-01229-y ↗
10. Kim · Exp. Mol. Med. · 2023 · 55 · 51010.1038/s12276-023-00965-7 ↗
11. Cai · Chem. Sci. · 2023 · 14 · 437510.1039/D2SC06036A ↗
12. Yang · J. Oncol. · 2023 · 2023 · 2733232
13. Huang · Sci. Rep. · 2022 · 12 · 2138610.1038/s41598-022-25998-2 ↗
14. Chai · Chem. Biodivers. · 2018 · 1510.1002/cbdv.201800314 ↗
15. Zhang · PLoS One · 2016 · 11
16. Liu · Acta Biochim. Biophys. Sin. · 2017 · 49 · 47910.1093/abbs/gmx033 ↗
17. Xu · ACS Appl. Mater. Interfaces · 2023 · 15 · 1747010.1021/acsami.2c21005 ↗
18. Liu · J. Control Release · 2020 · 328 · 110.1016/j.jconrel.2020.08.015 ↗
19. Furukawa · Science · 2013 · 34110.1126/science.1230444 ↗
20. Cun · Adv. Colloid Interface Sci. · 2022
21. Ding · Adv. Drug Deliv. Rev. · 2022
22. Wang · J. Sci. Adv. Mater. Dev. · 2023 · 8
23. Johnson · Nat. Nanotechnol. · 2018 · 13 · 98010.1038/s41565-018-0292-y ↗
24. Chen · Adv. Funct. Mater. · 2020 · 30
25. Ren · Int. J. Biol. Macromol. · 2021 · 191 · 109610.1016/j.ijbiomac.2021.09.184 ↗
26. Fu · Front. Bioeng. Biotechnol. · 2022 · 10
27. Zheng · J. Mater. Chem. B · 2016 · 4 · 124710.1039/C5TB02624E ↗
28. Guo · ACS Nano · 2023 · 17 · 1079210.1021/acsnano.3c02287 ↗
29. Villaseñor · Nat. Biotechnol. · 2020 · 38 · 72810.1038/s41587-020-0434-2 ↗
30. Pan · J. Control Release · 2023 · 357 · 13310.1016/j.jconrel.2023.03.041 ↗
31. Szabo · Annu Rev. Biophys. · 2023 · 52 · 22910.1146/annurev-biophys-092622-094853 ↗
32. Jin · Materials · 2023 · 68 · 108
33. Lin · ACS Appl. Mater. Interfaces · 2021 · 13 · 5069510.1021/acsami.1c13517 ↗
34. Wang · J. Nanobiotechnol. · 2022 · 20 · 7810.1186/s12951-022-01275-2 ↗
35. Bai · Adv. Sci. · 2021 · 8 · 210265810.1002/advs.202102658 ↗
36. Ahmad · Oncol. Targ. Ther. · 2021 · 182110.2147/OTT.S287354 ↗
37. Zhang · Nat. Commun. · 2022 · 13 · 494810.1038/s41467-022-32645-x ↗
38. Wartewig · Trends Immunol. · 2019 · 40 · 40310.1016/j.it.2019.03.005 ↗
39. Xie · Mol. Cancer · 2023 · 22 · 4610.1186/s12943-023-01732-y ↗
40. Fu · Toxicol. Mech. Methods · 2020 · 30 · 16710.1080/15376516.2019.1701594 ↗
41. Guo · Adv. Mater. · 2023 · 35 · 221226710.1002/adma.202212267 ↗
42. Huang · Bioact. Mater. · 2023 · 21 · 381
43. Zhang · Nat. Commun. · 2019 · 10 · 170410.1038/s41467-019-09566-3 ↗
44. Yang · Phytomedicine · 2024 · 122
45. Tsvetkov · Science · 2022 · 375 · 125410.1126/science.abf0529 ↗
46. Garza · Trends Endocrinol. Metab. · 2022 · 34 · 2110.1016/j.tem.2022.11.001 ↗
47. Zhao · Theranostics · 2021 · 11 · 184510.7150/thno.50905 ↗
48. Guo · Trends Pharmacol. Sci. · 2022 · 43 · 95710.1016/j.tips.2022.08.006 ↗
49. Xu · Adv. Funct. Mater. · 2022 · 32
50. Liu · J. Nanobiotechnol. · 2020 · 18 · 1
51. Wculek · Nat. Rev. Immunol. · 2020 · 20 · 710.1038/s41577-019-0210-z ↗
52. Galluzzi · Nat. Rev. Immunol. · 2017 · 17 · 9710.1038/nri.2016.107 ↗
53. Zheng · ACS Nano · 2023 · 17 · 997210.1021/acsnano.2c11964 ↗
54. Jin · J. Biomed. Nanotechnol. · 2014 · 10 · 239310.1166/jbn.2014.1898 ↗
55. Mao · Biomaterials · 2019 · 188 · 17310.1016/j.biomaterials.2018.10.012 ↗